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Abstract.  In the preceding report (Kelvin, D. J., G. 
Simard,  H. H. Tai,  T.  P. Yamaguchi,  and J. A. Con- 
nolly.  1989. J.  Cell Biol.  108:159-167) we demon- 
strated that pertussis toxin (PT) blocked proliferation 
and induced differentiation in BC3H1 muscle cells. In 
the present study, we have used PT to examine specific 
growth factor signaling pathways that may regulate 
these processes. Inhibition of [3H]thymidine  by PT in 
20%  FBS was reversed in a dose-dependent fashion by 
purified fibroblast growth factor (FGF).  In 0.5 % FBS, 
the normally induced increase in creatine kinase (CK) 
activity was blocked by FGF in both the presence and 
absence of PT.  Similar results were obtained with 
purified epidermal growth factor (EGF). We subse- 
quently examined the effect of a  family of growth fac- 
tors linked to inositol lipid hydrolysis and found that 
thrombin,  like FGE would increase [3H]thymidine  in- 
corporation and block CK synthesis.  However, PT 
blocked thymidine incorporation induced by thrombin, 
and blocked the inhibition of CK turn-on  in 0.5 % FBS 
by thrombin.  The ras oncogene, a G  protein homo- 
logue, has previously been shown to block muscle cell 
differentiation in C2 muscle cells (Olson,  E.  N., G. 
Spizz, and M.  A. Tainsky.  1987. Mol.  Cell.  Biol. 
7:2104-2111);  we have characterized a BC3H1 cell 
line, BCT31, which we transfected with the val n onco- 
genic Harvey ras gene.  This cell line did not express 
CK in response to serum deprivation.  Whereas [3H]- 
thymidine incorporation  was inhibited by 70-80%  by 
increasing doses of PT in control cells, BCT31 cells 
were only inhibited by 15-20%.  ADP ribosylation 
studies indicate this PT-insensitivity is not because of 
the lack of a PT substrate in this cell line.  Further- 
more,  PT could not induce CK expression in BCT31 
cells as it did in parental cells. We conclude that there 
are at least two distinct growth factor pathways that 
play a key role in regulating proliferation and differen- 
tiation in BC3H1 muscle cells, one of which is PT 
sensitive, and postulate that a G protein is involved in 
transducing  signals from the thrombin receptor.  We 
believe that ras functions in the transduction of growth 
factor signals in the nonPT-sensitive pathway or down- 
stream from the PT substrate in the second pathway. 
VIDENCE from a number of muscle cell systems indi- 
cates  that  the  control  of  myoblast  proliferation/ 
differentiation  is stochastic  and can be regulated  by 
extrinsic  factors  (Konigsberg,  1971, 1976; Linkhart  et al., 
1981, 1982; Compton et al., 1986; Clegg et al., 1987). More 
specifically, addition of the mitogen fibroblast growth factor 
(FGF) t  was  shown  to  prolong  proliferation  and  delay 
differentiation  in primary muscle cells (Gospadarowicz  et 
al.,  1976) and  the  MM14  clonal  mouse muscle cell  line 
D. Kelvin's present address is Laboratory of Molecular Immunoregulation, 
Biological Response Modifier Program, National Cancer Institute, Freder- 
ick Cancer Research Facility, Frederick,  MD 21701. 
1. Abbreviations used in this paper:  CK, creatine kinase; FGF, fibroblast 
growth factor; PT, pertussis toxin. 
(Linkhart  et al.,  1981, 1982;  Clegg  et al.,  1987),  and  its 
removal for even short periods of time (2-3 h) triggers termi- 
nal differentiation  in the MM14 line. 
The role of FGF in inducing muscle-specific  gene expres- 
sion has been examined in detail in BC3H1 muscle cells. If 
purified  FGF is added to differentiated  cells in 0.5%  FBS, 
the level of CK declines (Lathrop et al., 1985a), and the level 
of creatine  kinase  (CK)  mRNA synthesized  is reduced by 
at least  10-fold within 24 h (Spizz et al.,  1986). However, 
purified FGF has been reported not to induce thymidine in- 
corporation or proliferation  (Lathrop et al., 1985b; Spizz et 
al.,  1986; Wice et al.,  1987). Rather, cells move from GO 
to a point 4-6 h into the G1 portion of the cell cycle, and this 
has been reported  with both acidic  (Lathrop  et al.,  1985b) 
and basic FGF (Wice et al.,  1987). 
How are signals  transduced  from the FGF receptor to 
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al. (1985) reported that FGF could stimulate protein kinase 
C and Ca  2÷ mobilization in fibroblasts.  However, Magnaldo 
et  al.  (1986) have  concluded that early mitogenic events 
mediated by FGF in hamster lung fibroblasts are not coupled 
to phospholipase C activation or inositol lipid breakdown, 
and more recently FGF has been shown to stimulate tyrosine 
kinase activity in 3T3 cells (Coughlin et al.,  1988).  More- 
over,  partially purified FGF receptors have been reported 
to have an associated tyrosine kinase activity (Huang and 
Huang,  1986).  Consistent with this evidence, Wice et al. 
(1987) found that vanadate, an inhibitor of tyrosine-specific 
protein phosphatases,  would mimic the effects of FGF in 
BC3HI cells, and cause these ceils to repress c~-actin and 
CK synthesis and to exit the GO portion of the cell cycle 
(Wice et al., 1987). These authors conclude that FGF is most 
likely working by the activation of tyrosine-specific protein 
kinases. 
As muscle differentiation may be regulated by multiple 
growth factors, GTP binding G  proteins are also obvious 
candidates to serve a signal transduction role; they have been 
shown to be involved in transducing signals from a variety 
of  receptors,  including  growth  factor  receptors  (Taylor, 
1986;  Taylor and Merritt,  1986;  Cockroft, 1987; Gilman, 
1987; Lefkowitz and Caron, 1988). In the preceding manu- 
script  (Kelvin et al.,  1989),  we demonstrated that a  PT- 
sensitive site is involved in this regulation in BC3H1 muscle 
cells. PT will block thrombin-induced hydrolysis of phos- 
phatidyl-inositol 4,5-bisphosphate  by phospholipase  C  as 
well as the stimulatory effects of thrombin on cell prolifera- 
tion in hamster lung fibroblasts (Magnaldo et al., 1986; Paris 
and Pouyssegur, 1986, 1987; Paris et al.,  1987; Chambard 
et al.,  1987).  Since PT will ADP ribosylate a G protein in 
these cells, it has been proposed that PT exerts its effects by 
blocking signals transduced by a G protein coupled to growth 
factor receptors. 
Another member of the class of G proteins that has been 
linked to the transduction of signals from cell surface recep- 
tors is p21  ras  (for reviews see Cooper and Lane,  1984; 
Levinson,  1986;  Barbacid,  1987).  The  ras  protein  has 
significant homology to the c~-subunit of transducin and the 
a-subunit of Go (Hurley et al., 1984; Lochrie et al.,  1985; 
Tanabe et al.,  1985).  The homologous regions correspond 
most closely with regions believed to be involved in guanine 
nucleotide binding and GTPase activity of ras suggesting 
that the ras protein may function as a signal transducing G 
protein. This idea has been supported by the demonstration 
that microinjection of antibodies to  ras  will block  nerve 
growth factor-induced neurite extension in PC-12 cells (Ha- 
gag et al.,  1986), the serum-induced expression of c-fos in 
quiescent fibroblasts (Stacey et al.,  1987),  and serum- or 
growth factor-induced thymidine incorporation in quiescent 
fibroblasts (Mulcahey et al.,  1985). 
Olson and co-workers have demonstrated that oncogenic 
H-ras or N-ras would completely block myogenic differenti- 
ation in transfected C2 myoblasts (Olson et al., 1987; Gossett 
et al., 1988). We have previously shown that transfection of 
BC3H1 cells with the oncogenic form of Harvey ras could 
modulate  differentiation in  BC3H1  cells  (Kelvin  et  al., 
1987); similar results have also been reported by Payne et al. 
(1987)  for transfected BC3HI  cells.  Furthermore,  it  was 
shown  that  ras-transfected  BC3H1  cells  did  not  express 
Ca  2÷ and Na  ÷ channels, membrane ion channels that appear 
after prolonged mitogen withdrawal (Caffrey et al.,  1987). 
In this study we have used PT to examine growth factor sig- 
naling pathways in BC3H1 muscle cells. We now report that 
both  FGF  and  thrombin  will  stimulate proliferation and 
block differentiation in  BC3H1  cells.  However,  the  FGF 
effect is not blocked by PT, but the thrombin effect is. BC3H1 
cells transfected with the ras oncogene do not differentiate. 
Moreover, these cells are much less sensitive to the growth 
inhibitory effects of PT, and it will not induce differentiation 
in these cells. We believe that the ras protein may be involved 
in  regulating  proliferation  and  differentiation  signals  in 
BC3H1 cells but at a site downstream from the PT site, or 
in a different pathway. 
Materials and Methods 
Cell Culture 
BC3H1  mouse muscle cells (Schubert et al., 1974) were cultured as previ- 
ously described (Kelvin et al.,  1989).  In some experiments, cells were 
switched to a serum-free medium (designated ITS) consisting of DME sup- 
plemented with antibiotics and insulin (15/~g/ml), transferrin (15 p.g/ml), 
and selenium (5 ng/ml). The detailed growth characteristics of this cell line 
in ITS medium has been reported previously (Kelvin et al.,  1988). 
Proliferation and Differentiation 
SH incorporation, cell counts, and CK assays were all performed as previ- 
ously described (Kelvin et al.,  1986;  Simard and Connolly, 1987; Kelvin 
et al.,  1989). 
Transfection 
BC3H1  cells in the logarithmic phase of growth were transfected by the 
CaPOn method with pHO plasmid DNA  (Spandidos and Wilkie,  1984; 
Graham and Van der Eb, 1973). The pHO6T1 plasmid conlains the activated 
I24 Ha-ms gene (yap z) as well as the aph gene which confers resistance 
to the neomycin analog G418. In addition, a control plasmid with no ras 
gene, designated pHO6, was constructed by removal of the ras gene. Cell 
lines were selected by treatment with 200 ~g/ml of (3418. After •3-4  wk, 
stable cell lines, capable of growing in (3418, were obtained. These lines 
were maintained in the absence of (3418 although periodic growth in 13418 
indicated the cell lines used retained the resistance phenotype (data not 
shown). 
Northern and Southern Blot Analysis 
For Southern blot analysis total genomic DNA was isolated from 107 cells 
(Maniatis et al.,  1982).  Aliquots of DNA were digested with Eco RI, sub- 
jected to electrophoresis on an agarose gel, transferred to a nitrocellulose 
filter, hybridized with a Barn H1 to Barn HI EJ ras fragment isolated from 
the pHO6T1  plasmid (labeled by nick translation with 32p dCTP),  and 
washed under low stringency conditions (Maniatis et al.,  1982). 
For Northern analysis, cytoplasmic RNA was isolated, subjected to elec- 
trophoresis, and transferred as described (Kelvin et al.,  1989).  Blots were 
hybridized with a Kpn 1 to Sac 1 EJ ras fragment isolated from the pHO6T1 
plasmid (labeled by nick translation with 32p dCTP),  and washed under 
high stringency conditions (Maniatis et al.,  1982). 
Materials 
Acidic FGF and EGF were obtained from R  &  D  Systems, Inc.  (Min- 
neapolis, MN) PT was from List Biological Laboratories, Inc. (Campbell, 
CA) and human thrombin from Calbiochem Behring Corp.  (San Diego, 
CA).  Purified human c~-thrombin  was a  generous gift of Dr.  J.  Ofosu, 
McMaster University (Hamilton, Canada). 
Results 
In the preceding paper (Kelvin et al., 1989), we showed that 
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um, a  medium which normally promotes proliferation and 
prevents differentiation,  not only do the cells stop growing 
but the  synthesis of CK is induced.  In this study,  we have 
used PT in an attempt to elucidate signaling pathways that 
regulate proliferation and differentiation in BC3H1  cells. 
FGF blocks differentiation in BC3H1 cells. Does PT work 
by blocking signals from the FGF receptor? In all experi- 
ments, we used PT at 10 ng/ml, a dose that produced maxi- 
mal inhibition of [3H]thymidine incorporation and maximal 
stimulation of CK activity. If exponentially growing cells in 
20% FBS growth medium were incubated with varying doses 
of purified acidic FGF and PT simultaneously, the PT de- 
pression of [3H]thymidine incorporation was eliminated in 
a dose-dependent fashion with a  half-maximal effect at '~1 
ng/ml FGF (Fig.  1 a). At high doses of FGF, thymidine in- 
corporation  was stimulated  to greater than control  values, 
and this has also been consistently seen in other experiments 
with high doses of FGF in the absence of PT (data not shown). 
Similar results were also seen if cells rendered quiescent 
by serum starvation were incubated with FGF in ITS serum- 
free medium (Fig.  1 b).  In contrast to previous reports in 
which BC3H1 cells switched to 0.5 % medium supplemented 
with FGF showed no appreciable pH]thymidine incorpora- 
tion (Lathrop et al.,  1985a, b; Wice et al.,  1987),  we have 
found significant  [3H]thymidine  incorporation at higher doses 
of FGF in this serum-free medium. Half-maximal stimula- 
tion was seen at '~3 ng/ml of FGF, and this stimulation was 
not inhibited by incubation  with  10 ng/ml PT (Fig.  1 b). 
To test the possibility that FGF somehow blocked the PT 
effect extraceUularly, we first treated BC3H1 cells with PT 
for 24 h in 20% FBS. This dramatically reduced the level of 
[3H]thymidine  incorporation.  If FGF  was  added  to  these 
"quiescent" cells,  a  single high dose (30 ng/ml) stimulated 
DNA synthesis severalfold in the continued presence of PT 
(data not shown). 
Acidic FGF (30 ng/ml) almost completely blocked the ap- 
pearance of CK activity in cells shifted to 0.5 % FBS. On the 
other hand, PT potentiated this response by ~50%  (Fig.  1 
c). When PT and FGF were added at the same time, the cells 
expressed very low levels of CK after 4 d (Fig. 1 c), and these 
were not significantly different from cells treated with FGF 
alone. When varying doses of FGF were added in either the 
presence or absence of PT, half-maximal inhibition was seen 
between  1 and  3  ng/ml  FGF  (data  not  shown).  Taken to- 
gether, these results provide strong evidence that FGF is act- 
ing via a  PT-insensitive pathway to  stimulate proliferation 
and inhibit differentiation in BC3HI muscle cells. 
EGF has also been reported to stimulate cell proliferation 
and to block CK and actin synthesis in BC3H1 cells (Wang 
and Rubenstein,  1988).  Cells rendered quiescent by serum 
starvation were incubated with varying doses of EGF in ITS 
medium (Fig. 2 a).  [3H]Thymidine incorporation was stim- 
ulated by EGF (half-maximal stimulation between  1 and 3 
ng/ml), and this effect was insensitive to PT. Like FGF, EGF 
would also inhibit CK activation if added when cells were 
switched to differentiation medium, and this inhibition was 
largely PT insensitive (Fig. 2 b). Half-maximal inhibition of 
differentiation was seen between 1 and 3 ng/ml of EGF (data 
not shown). 
The fact that PT induced differentiation in 20% FBS sug- 
gested it was blocking a mitogenic signal in serum that nor- 
Figure  1.  FGF  effects on 
thymidine  incorporation  and 
CK  expression  in  BC3Ht 
cells. (a) Exponentially grow- 
ing cells in 20% FBS were in- 
cubated  simultaneously  with 
PT (except control  [C] cells) 
and  varying  doses  of acidic 
FGE  Thymidine  incorpora- 
tion was measured 48 h later. 
(b) Cells were rendered quies- 
cent by transfer to serum-free 
ITS medium. Increasing doses 
of acidic FGF were added in 
the presence or absence of PT 
and  thymidine  incorporation 
was measured 48 h later. (c) 
Cells  were switched to 0.5% 
FBS medium to induce differ- 
entiation, and CK was activity 
measured  4  d  later. Pair  of 
bars (left), cells Jr PT. Pair of 
bars (right), cells  +  FGF (30 
ng/ml)  +  PT.  CK  activity 
was the mean of  three separate 
determinations;  in  this  and 
succeeding histograms repre- 
senting CK activity, it is ex- 
pressed  as  a  percentage  of 
control  activity, with the CK 
activity  in  control  cells  in 
0.5%  FBS  medium  taken  as 
10o%. 
mally represses muscle protein synthesis.  The present data 
indicate this signal is not FGF or EGE A family of growth 
factors stimulate the formation of inositol phosphates in re- 
sponse to factor binding to cell surface receptors (e.g., Ber- 
ridge et al.,  1984;  Brown et al.,  1984; Carney et al.,  1985; 
Heslop et al.,  1986;  Takuwa et al.,  1987),  and this can be 
blocked by PT (e.g., Paris and Pouyssegur, 1986). Thus, we 
tested the ability of varying doses of several of these growth 
Figure  2.  EGF  effects on 
thymidine  incorporation  and 
CK expression in BC3H1 cells. 
(a) Cells were rendered quies- 
cent  by switching  to  serum- 
free  ITS  medium.  Varying 
doses of EGF were added in 
the presence or absence of PT 
and  thymidine  incorporation 
was measured 48 h later. (b) 
Cells  were switched to 0.5% 
FBS medium to induce differ- 
entiation, and CK activity was 
measured  4  d  later. Pair  of 
bars (lefO, cells 5- PT. Pair of 
bars (right), cells +  EGF (30 
ng/ml)  _+ PT. 
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cells  in  serum-free  medium.  Little  or  no  stimulation  was 
seen with gastrin releasing peptide or vasopressin and vari- 
able  results  were obtained with  bombesin and bradykinin. 
However,  thrombin  consistently  stimulated  [3H]thymidine 
incorporation in quiescent cells in a dose-dependent fashion 
(Fig.  3  a).  Furthermore,  this  stimulation  was  inhibited  by 
simultaneous incubation with 10 ng/ml PT (Fig. 3 b). In 20% 
FBS,  when cells  were treated  simultaneously  with  PT and 
thrombin, even very high doses of thrombin (100 nM) could 
not overcome the inhibitory effect of PT (Fig.  3  c).  In this 
particular experiment, thymidine incorporation was only in- 
hibited  by  ~30-40%  by PT;  however,  similar  results  have 
been seen  in other experiments  in which greater  inhibition 
was seen with PT (data not shown). If cells were first treated 
with PT for 24 h, and then thrombin was added, a high dose 
of thrombin (50 nM) could not increase thymidine incorpo- 
ration in the continued presence of PT although FGF could 
(data  not shown). 
Like FGF and EGF, thrombin (10 nM) also inhibited CK 
induction in cells switched to differentiation medium (0.5 % 
FBS; Fig. 3 d).  In this experiment,  ~37%  of the amount of 
CK  in control  cells  was present  in thrombin-treated  cells. 
However,  if PT  was  added  with  thrombin,  this  inhibitory 
effect was abolished  (Fig.  3  d).  We have  subsequently  re- 
peated  these  experiments  with  purified  c~-thrombin,  and 
found  it  will  stimulate  thymidine  incorporation  and  com- 
pletely  block CK activation  in BC3HI  cells.  These effects 
were completely reversed by PT (A. Sue-A-Quan, G. Simard, 
J.  A.  Connolly,  unpublished  results). 
Figure 3.  Thrombin effects on thymidine  incorporation and CK ex- 
pression in BC3H1 cells.  (a) Cells  were  rendered  quiescent  by a 
switch  to  ITS  medium,  varying doses  of thrombin  added,  and 
thymidine incorporation was determined  28 h later. (b) Quiescent 
cells were incubated  with thrombin (10 nM) in the presence or ab- 
sence of PT, and thymidine  was incorporation determined.  (c) Ex- 
ponentially  growing cells in 20% FBS were incubated with PT (10 
ng/ml) and increasing doses of thrombin. (d) Cells were switched 
to 0.5 FBS to induce differentiation,  and CK activity was measured 
4 d later. Pair of bars (left),  cells  +  PT. Pair of bars (right),  cells 
+  thrombin (10 nM)  +  PT. 
We have found that FGF and thrombin will stimulate thy- 
midine incorporation in serum-starved BC3H1 cells. Similar 
results  were  obtained  if labeled  nuclei  were  counted after 
tritiated thymidine autoradiography (data not shown). Thus, 
a  significant proportion of these cells have transited the GI 
phase of the cell cycle and entered into S phase. To determine 
if these cells were capable of proliferating in response to ei- 
ther of these growth factors alone, we measured cell number 
over time.  In cells  switched to 0.5 %  FBS or ITS, and sup- 
plemented with either FGF (30 ng/ml) or thrombin (10 nM), 
there was no significant increase in cell number over 5 d (Fig. 
4). Thus, it appears these cells require more than one factor 
to transit through the cell cycle. Furthermore, the amount of 
thymidine incorporation or the percentage of labeled nuclei 
seen with a  single growth factor was much lower than that 
seen with 20% FBS stimulation. In a separate study, we have 
found that the sequential  exposure of cells to FGF and EGF 
gave  thymidine  incorporation  values  similar  to 20%  FBS 
medium and induced cell proliferation (Kelvin et al.,  1988). 
These  results  suggest  that  thrombin  is  exerting  effects  on 
proliferation  and  differentiation  in  BC3H1  cells  in  a  PT- 
sensitive pathway, and that G proteins may play a crucial role 
in transmitting  such  signals. 
As the  ras  oncogene,  another  member of the  G  protein 
family, has previously been shown to block myogenic differ- 
entiation  in  C2  cells  (Olson  et  al.,  1987;  Gossett  et  al., 
1988),  we  examined  the  effects  of PT  on  ras-transfected 
BC3H1 cells.  Cells were transfected with the pHO6T1 plas- 
mid containing the val ]2 Harvey ras oncogene, and we have 
characterized one of these transfected cell lines,  designated 
BCT31.  Southern analysis indicated that this cell line stably 
incorporated the ras oncogene (Fig. 5 a), and Northern anal- 
ysis with a human ras probe indicated that significant levels 
of mRNA were expressed from this transfected gene (Fig. 5 
b). BCT31 cells did not express significant levels of CK, even 
after 4 d in 0.5%  FBS (Fig. 5 c). In addition,  these cells re- 
mined  a  myoblast-like  morphology  and  failed  to  express 
significant levels of acetylcholine receptors, another marker 
of muscle differentiation (data not shown). Cells transfected 
with the pHO6 plasmid, which does not contain a ras gene, 
were not significantly different from control cells in their ex- 
pression of muscle proteins  (data not shown). 
We examined the ability of PT to inhibit thymidine incor- 
poration in BC3H1 and BCT31 cells in 20%  FBS (Fig. 6 a). 
Although PT would inhibit incorporation by up to 80%  in a 
dose-dependent fashion in control cells,  it only reduced in- 
corporation by ~20%  in BCT31  cells  (Fig.  6  a).  Further- 
more,  when  we  examined  [3H]thymidine  incorporation  in 
BCT31 cells and control BC3HI cells in the presence of PT 
(10 ng/ml),  the amount of thymidine incorporation induced 
by EGF (50 ng/ml) in serum-free ITS medium was found to 
-4-  ,5%+FGF 
~  15 
._1o 
0 
1  2  3  4  S 
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Figure 4. Effect of growth fac- 
tors on proliferation  of  BC3HI 
cells.  Cells  were  switched  to 
0.5 FBS medium in the pres- 
ence or absence  of FGF  (30 
ng/ml)  or thrombin (10 mM) 
and  cell  number  was  mea- 
sured  at 24-h intervals. 
The Journal of Cell Biology, Volume 108, 1989  172 Figure  5.  Characterization  of ras-transfected  BCT31 cells.  (a) 
Southern blot analysis. DNA was probed with a 32P-labeled EJ ras 
fragment that hybridizes to both mouse and human genomic ras. (b) 
Northern blot analysis. Cytoplasmic RNA was probed with a 32p_ 
labeled EJ ras fragment that hybridizes predominantly to human El 
ms RNA.  (c)  CK activity  was determined  4  d  after switching 
BCT31 or parental BC3H1 cells to fresh 20% or 0.5 FBS. 
be 88% (for BC3H1) and 93% (for BCT31) of the values ob- 
tained in the absence of PT. These data indicate that BCT31 
cells were largely insensitive to the effects of PT on [3H]thy- 
midine incorporation. 
BCT31 EJ ras-transfected cells do not express detectable 
levels of CK in 0.5%  FBS (Fig. 5 b). Incubation of BCT31 
Figure  6.  PT  sensitivity  of 
proliferation  and  differentia- 
tion  in  BCT31 ceils.  Cells 
were plated in 20%  FBS. (a) 
24 h later, varying doses of  PT 
were added, and 24 h after PT 
addition, [3H]thymidine incor- 
poration was determined. Each 
point represents the average of 
two separate samples. (b) 24 h 
later,  cells  were  switched to 
fresh 20% FBS or 0.5% FBS 
in the presence or absence of 
PT. 96 h later, CK activity was 
determined. Each point repre- 
sents  the  mean  of triplicate 
determinations. 
cells with 10 ng/ml PT did not induce any detectable CK ac- 
tivity in 20% FBS or 0.5% FBS although PT induced higher 
levels of CK activity in  both serum conditions  in  BC3H1 
cells (Fig. 6 b). The inability of PT to block proliferation or 
induce differentiation in BCT31 cells was not the result of a 
lack of substrate for this toxin.  A  similar, 40 kD substrate 
was ADP ribosylated in both BCT31 and BC3HI cells (Fig. 
7  a).  Furthermore,  this  ribosylation  in  BCT31  cells  was 
blocked by preincubation of these cells with increasing doses 
of PT (Fig.  7 b). 
Discussion 
These results demonstrate that both FGF and EGF are capa- 
ble  of stimulating  thymidine  incorporation  and  inhibiting 
differentiation in BC3H1 muscle cells in the presence of PT. 
Since PT can inhibit serum-induced proliferation and ADP 
ribosylates a  membrane-associated, intracellular substrate, 
presumably a G protein, these results suggest that there is a 
second pathway that is PT sensitive. The present data also 
suggest that thrombin is acting in this PT-sensitive pathway 
to promote proliferation and block differentiation in BC3H1 
cells. 
Several growth factors including  FGF,  EGF,  and TGF-/3 
have been shown to modulate muscle cell differentiation (for 
review see Florini and Magri,  1988).  Recently, it has been 
proposed that FGF can act as a morphogen to induce meso- 
dermal lineages in Xenopus animal pole ceils (Slack et al., 
1987) and this can be potentiated by TGF-/3 (Kimelman and 
Kirschner,  !987).  Intriguingly,  Seed and Hauschka (1988) 
recently  reported that  FGF  induced  differentiation in  one 
population of chick limb bud myoblasts but blocked it in a 
second.  As  far as we know,  this current  study is the  first 
demonstration that thrombin can modulate muscle cell pro- 
liferation or differentiation.  Thrombin could work alone or 
in conjunction with other growth factors during commitment 
or the regulation of differentiation in muscle.  We are cur- 
rently  examining  thrombin  effects on  skeletal muscle  cell 
lines and primary muscle cell cultures. 
It is interesting to note that PT inhibits BC3H1 cell growth 
in high serum (20% FBS) medium but does not block signals 
from FGF or EGF receptors. PT will also block thymidine 
incorporation by 30-50% and decrease proliferation of 3T3 
cells stimulated with serum-containing medium (Hildebrandt 
et al.,  1986) although this cell line has receptors for a wide 
variety of growth factors (Heslop et al.,  1986;  Berridge et 
al.,  1984;  Brown and Blakeley,  1983;  Tsuda et al.,  1985; 
Macphee  et  al.,  1984;  Zachary  et  al.,  1986).  Similarly, 
Chambard et al. (1987)  found that EGF and FGF stimulated 
thymidine incorporation in lung fibroblasts in a PT-insensi- 
tive  manner,  but  PT  reduced  thymidine  incorporation  by 
85 % in serum-containing medium. One possible explanation 
for this paradox is that the levels of EGF and FGF in the 
serum may be quite low, and growth factors working in a PT- 
sensitive pathway account for the majority of serum-stimu- 
lated growth in BC3H1 cells. Consistent with this interpre- 
tation  is  our  observation that  cells  growing  in  20%  FBS 
medium supplemented with FGF have significantly higher 
levels of thymidine  incorporation  than  cells  in  20%  FBS 
medium alone. 
Our results are consistent with two independent signaling 
pathways  regulating  proliferation  and  differentiation  in 
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PT in BCT31 cells.  (a)  Cell 
membranes  were  prepared 
from  exponentially  growing 
cells in 20% FBS or differen- 
tiated cells (4 d in 0.5% FBS) 
from EJ ras-transfected  BCT31 
cells or parental BC3HI cells. 
(b)  Preincubation  of  intact 
BCT31 cells  with  increasing 
doses of PT prevented the PT- 
induced ADP ribosylation of 
this substrate in membranes. 
BC3H1 muscle cells. Similar results have been reported in 
other  cell  systems.  Letterio  et  al.  (1986)  found that  the 
bombesin-induced expression of c-myc and DNA synthesis 
in 3T3 cells could be blocked by PT, but PT had no effect 
on PDGF-induced proliferative responses.  Pouyssegur and 
co-workers have shown that c~-thrombin induces the hydroly- 
sis of phosphatidyl-inositol 4,5-bisphosphate in cells made 
quiescent by serum starvation (Paris and Pouyssegur, 1986; 
12Allemain et al.,  1986), and that this hydrolysis is blocked 
by PT (Paris and Pouyssegur, 1986,  1987). However, these 
cells are also stimulated to proliferate by EGF or FGF in a 
second,  PT-independent pathway  (Paris  and  Pouyssegur, 
1986;  Chambard et al.,  1987).  Because PT did not com- 
pletely inhibit thymidine incorporation, it remains a possi- 
bility that there are two distinct populations of BC3H1 cells, 
one sensitive to thrombin and another to FGF,  rather than 
both pathways being present in individual cells. However, the 
fact that purified ct-thrombin or acidic FGF could each com- 
pletely block CK turn-on would argue strongly against this 
possibility. 
We have also found that a BC3HI muscle cell line stably 
transfected with the EJ  ras  oncogene (designated BCT31) 
does not differentiate, and this result is consistent with recent 
reports  demonstrating  that  oncogenic H- or  N-ras-trans- 
fected C2 cells (Olson et al.,  1987; Gossett et al.,  1988) or 
H-ras-transfected  BC3H1 cells did not differentiate (Payne 
et al.,  1987).  ras thus becomes a candidate for acting in a 
signal-transducing pathway.  The goal of the present study 
was to try and identify where ras functioned in the transduc- 
tion of growth factor signals in BC3H1 cells. The rationale 
was that if ras functioned in the PT-sensitive pathway but be- 
fore the PT block then PT should rescue differentiation in EJ 
ras-transfected cells. Alternatively, if ras functioned in the 
PT pathway, but after the PT block then PT would not be able 
to rescue differentiation. Likewise if ras functioned outside 
of the PT toxin pathway then PT would also not be able to 
rescue differentiation. 
We found that PT toxin was not capable of rescuing the 
differentiation phenotype in EJ ras-transfected cells. We also 
found that EJ ras-transfected cells were capable of prolifer- 
ating in high concentrations of PT. These data indicate that 
ras functions after the PT block or in a PT-insensitive path- 
way. It is unlikely these results are due to the inability of PT 
to ADP ribosylate its  "normal" G  protein substrate as  no 
differences were seen in substrates ribosylated in BC3H1 or 
BCT31 cells. Furthermore, this does not reflect a difference 
between the endogenous p21 ras and the transfected human 
ras, as no substrates were seen to be ribosylated in the range 
of 21 kD (Fig. 7). Magee et al. (1987) have also reported that 
p21  (N-ras) could not be ADP ribosylated by PT. 
It has been proposed that p21  ras controls the activity of 
phospholipase C (Wolfman and Macara, 1987; Fleishman et 
al.,  1986;  Marshall,  1987).  However, Lacal et al.  (1987) 
reported that  ras-transfected  cells had  higher  constitutive 
levels of diacylglycerol, but levels of inositol phosphate were 
not affected; the report concluded that ras is working through 
another "novel" pathway to stimulate diacylglycerol produc- 
tion. Seuwen et al. (1988) found that expression of oncogenic 
Ha-ras  or Ki-ras did not abrogate the sensitivity of phos- 
pholipase C activation to PT, and concluded that the trans- 
forming potential of activated forms of ras  does not result 
from persistent activation of phospholipase  C.  Moreover, 
microinjected ras antibodies block mitogenic responses, in- 
duced by calcium ionophore and  12-O-tetradecanoyl phor- 
bol-13-acetate  (TPA), prostaglandin F2a, or phosphatidic acid 
(Yu et al.,  1988), strongly suggesting that ras does not con- 
trol phospholipase C-induced production of inositol phos- 
phates and Ca  2+ but rather functions downstream from these 
mitogenic signals. The data we have presented also suggest 
that ras is downstream of the PT site in growth factor signal- 
ing pathways.  Our hypothesis is summarized diagrammati- 
cally in Fig. 8. Two distinct pathways  are capable of regu- 
lating proliferation and differentiation in BC3H1 cells.  We 
speculate that ms functions in the PT-insensitive pathway; al- 
ternatively it may function at a common point or downstream 
of the PT substrate in the PT-sensitive pathway. We are cur- 
rently  investigating  the  functional  location  of  ras  using 
microinjected ras antibodies and growth factors. 
ras  stimulates  the  transcription  of genes  containing  a 
regulatory sequence to which the transcription factors jun/ 
AP-1 can bind (Wasylyk et al., 1987; Imler et al., 1988; Mer- 
rood et al., 1988), and several proliferation active genes con- 
rain this regulatory sequence, ras also induces fos gene ex- 
pression in NIH 3T3 cells and this fos gene expression is 
critical  for the  ras  or  TPA-induced activation of the  col- 
lagenase promoter, a promoter activated by jun/AP-1  (Schon- 
thai et al.,  1988).  Furthermore, los interacts directly with 
jun/AP-I to stimulate responsive genes (Chiu et al.,  1988; 
Sassone-Corsi et al., 1988), and TPA, serum, and EGF can 
stimulate  jun/AP-1  expression  (Quantin  and  Breathnach, 
1988;  Lamph  et al.,  1988;  Ryseck et ~.,  1988).  In  ras- 
transfected BCT31  cells,  such  transcription  factors could 
bind to regulatory sequences of proliferation-specific genes, 
and as a result inhibit muscle gene expression. It is interest- 
ing to note that the muscle-specific CK enhancer region is 
not functional in N-ras transfected C2 muscle cells (Olson, 
E., personal communication). Alternatively, these transcrip- 
tion factors may bind to regulatory sequences of a differentia- 
tion  "master  genes  analogous  to  the  recently  described 
myoD gene (Davis et al.,  1987), and inhibit its expression. 
Alternatively,  ras  may  activate  a  protein  that  inactivates 
myoD or differentiation-specific enhancer binding proteins. 
These interesting studies suggest a plausible mode whereby 
growth  factors  could  modulate  differentiation  in  muscle 
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Figure  8.  Model  for  signal  transducing  pathways  that  regulate 
proliferation and differentiation in BC3H1  cells. Two unique path- 
ways, only one of which is sensitive to PT,  are  indicated.  The  ras 
oncogene, which can also modulate proliferation and differentiation 
in these cells, has been hypothesized to be working in one of these 
pathways. 
cells, and  we are currently  investigating  the validity  of these 
possibilities. 
In summary,  we conclude  that two signal transducing  path- 
ways  identified  in  this  study  impinge  on  a  common  focal 
point  that promotes  proliferation  and  inhibits  differentiation. 
ras  functions  in  a  PT-insensitive  pathway  or  downstream 
from  the  PT  substrate  in  BC3H1  cells. 
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